VLA1553 full dose + VLA1553 half dose + Control
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chikungunya Virus Infection
Conditions
Chikungunya Virus Infection
Trial Timeline
Dec 18, 2023 → Jul 2, 2025
NCT ID
NCT06106581About VLA1553 full dose + VLA1553 half dose + Control
VLA1553 full dose + VLA1553 half dose + Control is a phase 2 stage product being developed by Valneva SE for Chikungunya Virus Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT06106581. Target conditions include Chikungunya Virus Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06106581 | Phase 2 | Completed |
Competing Products
20 competing products in Chikungunya Virus Infection